Commission decisions on applications for authorisation

The European Commission has granted an authorisation for the use of 4-(1,1,3,3-Tetramethylbutyl)phenol, ethoxylated (4-tert-OPnEO) by Pfizer Manufacturing Belgium NV (review period expires on 4 January 2030).